Accretion Pharmaceuticals came to market through an SME IPO that opened on 14 May 2025 and closed on 16 May 2025, and the shares listed on 21 May 2025 on NSE SME. The price band was ₹96 to ₹101 per share and one lot was 1200 shares, so the minimum application was ₹1,21,200. The issue size was ₹29.75 crore. The whole issue was fresh shares, so the money raised went to the company.
Kfin Technologies Limited was the registrar to the issue, and Jawa Capital Services Private Limited was the lead manager.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical firm that produces and markets tablets, capsules, and other health care products. The company provides contract manufacturing services as well. The Company produces and sells Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup).The company is also certified by ISO 9001:2015, ISO 14001:2015, and ISO 22000:2005, demonstrating its commitment towards quality and environmental management systems.
The manufacturing facility of the company is situated in Ahmedabad, Sanand, Gujarat.The company has spread its wings globally, representing itself in over 20 countries, with locations in Africa, Southeast Asia, as well as the Middle East. Product Portfolio and Services: Tablets and Capsules – Encompassing antibiotics, anti-inflammatory, pain management, cardiovascular, and gastrointestinal drugs. Oral Liquids and Syrups – For respiratory, pediatric, and gastrointestinal treatments.
External Preparations – Such as medicated lotions, gels, ointments, and dusting powders for skin treatment and dermatological therapy. Ayurvedic and Herbal Products – Emphasizing natural wellness remedies for immunity, digestion, and overall health. As of January 2025, the company has 83 employees (including 4 Executive Directors) on its payroll.
As described in the offer document.
| Metric | 31-Dec-24 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
|---|
Mr. Mayur Popatlal Sojitra, Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Hardik Mukundbhai Prajapati. Promoter holding 100% before the issue and 73.48% after.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Accretion Pharmaceuticals IPO was a ₹29.75 crore fixed-price issue, made up entirely of a fresh issue. It was priced at ₹96–₹101 per share with a lot size of 1,200 shares (₹1,21,200). The IPO was open from May 14 to May 16, 2025. Shares listed on NSE SME on May 21, 2025 at ₹79, a 21.8% discount to the issue price of ₹101. Kfin Technologies Limited is the registrar. Jawa Capital Services Private Limited is the book running lead manager.
The price band of Accretion Pharmaceuticals IPO is ₹96 to ₹101 per share.
The lot size of Accretion Pharmaceuticals IPO is 1200 shares.
The minimum investment for Accretion Pharmaceuticals IPO is approximately ₹1,21,200 based on the upper price band.
The allotment date of Accretion Pharmaceuticals IPO is May 19, 2025.
You can check Accretion Pharmaceuticals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Accretion Pharmaceuticals IPO allotment status on Rupix for quick and easy access.
₹96 to ₹101 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 1200 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,21,200. After listing, SME shares also trade in lots rather than one share at a time.
₹1,21,200, for one lot of 1200 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 14 May 2025 and closed on 16 May 2025.
The basis of allotment was published on 19 May 2025 by Kfin Technologies Limited, and allotted shares were credited to demat accounts before listing.
The shares listed on 21 May 2025 on NSE SME.
The issue size was ₹29.75 crore. The fresh issue was 29,46,000 shares (aggregating up to ₹29.75 crore).